Posted by Michael Wonder on 05 Aug 2015
PHARMAC is seeking feedback on a proposal for various pharmaceuticals (including new listings, amendments to funding restrictions and a delisting) ...
Read more →
Posted by Michael Wonder on 05 Aug 2015
The outcome statements from the February 2015 Drug Utilisation Sub Committee meeting are now available on the PBS website. ...
Read more →
Posted by Michael Wonder on 05 Aug 2015
AbbVie, a global biopharmaceutical company, today announced that the Common Drug Review (CDR) has posted the Canadian Drug Expert Committee ...
Read more →
Posted by Michael Wonder on 05 Aug 2015
The NHS is to delay the introduction of a highly expensive drug that can save the lives of people infected ...
Read more →
Posted by Michael Wonder on 05 Aug 2015
The National Institute for Health and Clinical Excellence is consulting once again on the use of Celgene’s Revlimid (lenalidomide) in ...
Read more →
Posted by Michael Wonder on 05 Aug 2015
[:content [\1 \space \F \e \b \r \u \a \r \y \space \2 \0 \1 \4 \space \- \space \T \h \e \space \F \e \b \r \u \a \r \y \space \2 \0 \1 \4 \space \u \p \d \a \t \e \space \t \o \space \t \h \e \space \N \e \w \space \Z \e \a \l \a \n \d \space \P \h \a \r \m \a \c \e \u \t \i \c \a \l \space \S \c \h \e \d \u \l \e \space \i \s \space \o \u \t \space \a \n \d \space \n \o \w \space \i \n \space \e \f \f \e \c \t \. " ..."]]
Read more →
Posted by Michael Wonder on 05 Aug 2015
The French government, looking to cut healthcare costs, plans to authorize the use of Roche cancer drug Avastin (bevacizumab) as ...
Read more →
Posted by Michael Wonder on 05 Aug 2015
[:content [\P \e \r \t \u \z \u \m \a \b \space \( \P \e \r \j \e \t \a \) \ \w \a \s \space \l \a \u \n \c \h \e \d \space \i \n \space \G \e \r \m \a \n \y \space \i \n \ \M \a \r \c \h \space \2 \0 \1 \3 \space \f \o \r \space \u \s \e \ \a \s \space \a \d \j \u \n \c \t \i \v \e \space \t \h \e \r \a \p \y \space \b \y \space \c \e \r \t \a \i \n \space \p \a \t \i \e \n \t \s \space \w \i \t \h \space \a \d \v \a \n \c \e \d \ \H \E \R \2 \- \p \o \s \i \t \i \v \e \space \b \r \e \a \s \t \space \c \a \n \c \e \r \. \ " ..."]]
Read more →
Posted by Michael Wonder on 05 Aug 2015
CADTH is hosting a series of lectures by prominent scholars and opinion leaders to share their perspectives on some of ...
Read more →
Posted by Michael Wonder on 05 Aug 2015
[:content [\E \i \s \a \i \space \h \a \s \space \s \a \i \d \ \t \h \a \t \space \i \t \space \w \i \l \l \space \t \e \m \p \o \r \a \r \i \l \y \space \s \u \s \p \e \n \d \space \s \a \l \e \s \space \o \f \space \F \y \c \o \m \p \a \space \( \p \e \r \a \m \p \a \n \e \l \) \space \i \n \space \G \e \r \m \a \n \y \space \a \s \space \i \t \space \\ \" \i \s \space \u \n \a \b \l \e \space \t \o \space \a \c \c \e \p \t \space \t \h \e " ..."]]
Read more →
Posted by Michael Wonder on 05 Aug 2015
[:content [\T \e \r \i \f \l \u \n \o \m \i \d \e \space \( \A \u \b \a \g \i \o \) \space \h \a \s \space \b \e \e \n \space \a \p \p \r \o \v \e \d \space \i \n \space \G \e \r \m \a \n \y \space \s \i \n \c \e \space \A \u \g \u \s \t \space \2 \0 \1 \3 \space \f \o \r \space \a \d \u \l \t \s \space \w \i \t \h \space \r \e \l \a \p \s \i \n \g \space \r \e \m \i \t \t \i \n \g \space \m \u \l \t \i \p \l \e \space \s \c \l \e \r \o \s \i \s \. \space \I \n \space \a \n \space \e \a \r \l \y " ..."]]
Read more →
Posted by Michael Wonder on 05 Aug 2015
CADTH has received notice of a pending submission from Cubist for Sivextro (tedizolid phosphate) for patients with an acute bacterial skin and ...
Read more →
Posted by Michael Wonder on 05 Aug 2015
UK trade associations, politicians, payors and patients have met with the European Medicines Agency to discuss the pros and cons ...
Read more →
Posted by Michael Wonder on 05 Aug 2015
[:content [\6 \space \M \a \y \space \2 \0 \1 \4 \space \- \ " ..."]]
Read more →
Posted by Michael Wonder on 05 Aug 2015
The drug abiraterone can add four months to the lives of men with advanced prostate cancer if given before chemotherapy, ...
Read more →